Rezolute shares plunge on disappointing Phase 3 congenital hyperinsulinism trial results

Rezolute shares plunged roughly 90% to $1.15 after its Phase 3 sunRIZE study of ersodetug in congenital hyperinsulinism failed to meet the primary endpoint—at the highest 10 mg/kg dose weekly hypoglycemia events fell about 45% versus a ~40% reduction on placebo (not statistically significant)—and the key secondary (average daily percent time in hypoglycemia) also missed despite a 25% reduction at the top dose versus a ~5% increase on placebo. The company said target drug concentrations were achieved and safety was generally favorable, though two participants had serious hypersensitivity reactions and hypertrichosis was commonly reported. Rezolute plans to meet the FDA under its Breakthrough Therapy designation to discuss next steps; an ongoing Phase 3 upLIFT trial in tumor-related HI has topline results expected in H2 2026, and those readouts and regulatory discussions will be pivotal for the program’s value and strategy.

Analysis

Rezolute (RZLT) shares plunged roughly 90% to $1.15 after the Phase 3 sunRIZE study of ersodetug in congenital hyperinsulinism failed to meet its primary endpoint; at the 10 mg/kg dose weekly hypoglycemia events fell ~45% versus ~40% for placebo, a non‑statistically significant difference. The study also missed its key secondary endpoint—change in average daily percent time in hypoglycemia—despite a 25% reduction at the top dose versus a ~5% increase in placebo, indicating the observed treatment effects did not clear statistical thresholds.

The company reported that target drug concentrations were achieved across age groups and characterized safety as generally favorable, although two participants had serious hypersensitivity reactions leading to discontinuation and hypertrichosis was commonly reported. Rezolute said it will meet the FDA under its Breakthrough Therapy Designation to discuss next steps, signaling the regulatory dialogue will determine whether any alternative approval strategy or additional data will be required.

The market has materially repriced the program and equity, making near‑term value highly binary; the upcoming FDA discussion and topline results from the ongoing Phase 3 upLIFT trial in tumor‑related HI (toplines expected H2 2026) are the principal catalysts. High placebo response and the safety signals increase the likelihood regulators will seek further analyses or additional studies, implying sustained volatility and conditional recovery dependent on clear positive data or regulatory accommodation.

Key Decisions for Investors

• Reduce or exit RZLT exposure and avoid initiating new positions until the company publishes its statistical analyses and the FDA meeting clarifies the regulatory path, given the primary and secondary misses and ~90% share repricing
• If retaining exposure, materially downsize positions and hedge risk (for example with put options) because value now hinges on two binary catalysts: the FDA discussions and upLIFT topline readout in H2 2026
• Monitor company releases for subgroup analyses, safety adjudications, and any revised trial commitments; only consider rebuilding exposure on clear positive signals from the FDA or a successful upLIFT result